1. Home
  2. JZXN vs PMCB Comparison

JZXN vs PMCB Comparison

Compare JZXN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JZXN

Jiuzi Holdings Inc.

HOLD

Current Price

$1.82

Market Cap

16.2M

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.74

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JZXN
PMCB
Founded
2019
1996
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
5.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
JZXN
PMCB
Price
$1.82
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
849.5K
7.4M
Earning Date
03-05-2026
12-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$97,465.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.63
52 Week High
$312.80
$1.90

Technical Indicators

Market Signals
Indicator
JZXN
PMCB
Relative Strength Index (RSI) 54.65 40.11
Support Level $1.70 $0.68
Resistance Level $2.01 $0.78
Average True Range (ATR) 0.63 0.09
MACD -0.08 -0.02
Stochastic Oscillator 3.92 15.65

Price Performance

Historical Comparison
JZXN
PMCB

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: